** Shares of gene therapy firm Bluebird Bio BLUE.O down 8.7% at $4.08 premarket
** BLUE says privately held UK company Ayrmid Ltd has not submitted binding proposal to acquire it and has not obtained necessary financing
** Co in March received non-binding offer from Ayrmid for up to $110.5 million
** BLUE adds it continues to be at significant risk of defaulting on its loan covenants
** Co's board reaffirms its recommendation in support of transaction with Carlyle CG.O and SK Capital, while recommending all stockholders tender into current agreement by May 2
** BLUE agreed to be taken private by Carlyle and SK Capital Partners at discount in February
** As of last close, stock has fallen 46.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。